Latest Shareholder Funding News

Australian Gold and Copper Ltd (AGC) reports a significant milestone with a 38.5 million ounce silver-equivalent resource at its Achilles deposit, underpinning an ambitious 2026 exploration program across the South Cobar Basin.

Ardea Resources has successfully raised A$5 million through a placement and launched a A$2 million Share Purchase Plan to fund the next phase of its Kalgoorlie Nickel Project. The capital injection supports the finalisation of a key feasibility study and ongoing project development.

Ariadne Australia Ltd reported a modest net profit of $2.8 million for the half-year ended December 2025, underpinned by strong growth in its Orams Group investment and key strategic assets despite foreign exchange headwinds.

Celsius Resources has raised A$9.3 million through a well-supported institutional placement, strengthening its balance sheet to advance the financing and early development of its flagship MCB copper-gold project in the Philippines.

Kuniko Limited has raised A$3.75 million in a strongly supported placement to fast-track drilling and resource expansion at its Commonwealth Gold–Silver Project in NSW’s Lachlan Fold Belt. Phase I drilling is underway, with results expected in April 2026.

Horizon Minerals has successfully raised A$175 million through a two-tranche institutional placement, complemented by a planned A$10 million share purchase plan, to fund the development of its Black Swan Processing Hub near Kalgoorlie.

Minbos Resources has appointed Rob Newbold as Acting CEO following the resignation of Lindsay Reed, while grappling with administrative and shareholder challenges delaying its key phosphate project in Angola.

HighCom Limited has announced a successful A$7 million placement alongside a new Share Purchase Plan, aiming to accelerate sales and manufacturing upgrades in key markets.

Apollo Minerals welcomes a $2.8 million investment from Tribeca Investment Partners, marking a significant vote of confidence in its Couflens tungsten-gold project in southern France. This capital injection follows a recent $6.5 million raise and aims to accelerate exploration and development activities.

PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.

HeraMED Limited has completed a $3.2 million placement to fund its global rollout of digital maternity care solutions, backed by new and existing institutional investors.

Assetora Limited has announced a $4 million pro-rata rights issue priced at $0.16 per share, with half the offer underwritten by existing shareholders to strengthen its balance sheet and repay debt.